Clinical Trial Update: A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Doses of RV1729 for 28 Days in Patients With COPD [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics of repeat dosing with RV1729 for 28 days in patients with chronic obst…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• RV1729

Snippet

Sponsor: Respivert Ltd | Conditions: Chronic Obstructive Pulmonary Disease | Phase 1 | Status: COMPLETED